Side Effects Will Pressure Price Of Sanofi’s Zaltrap In Germany
This article was originally published in The Pink Sheet Daily
Germany’s IQWiG could not fault Sanofi’s Zaltrap on clinical effectiveness in colorectal cancer, but its identification of serious adverse incidents is likely to depress the drug’s price there.
You may also be interested in...
Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.